Senior Director - Urology, Andrology & Renal Transplant, BLK-Max Super Speciality Hospital, New Delhi, India
Part 5 of 17 in Diagnosis and Management of Prostate Cancer
Prostate Biopsy and MRI Fusion Biopsy: How Prostate Cancer Is Confirmed
August 7, 2026
A transrectal ultrasound-guided biopsy, increasingly combined with MRI fusion technology, is the definitive way to confirm prostate cancer once screening raises suspicion, and around 20 percent of men require more than one round of biopsy to reach a diagnosis. This step-by-step process is central to accurate prostate cancer diagnosis.
What Does Transrectal Ultrasound Show?
Dr. Shafiq Ahmad explains that prostate cancer typically arises from the peripheral zone of the prostate, which transrectal ultrasound is well suited to assess. A hypoechoic lesion seen on ultrasound carries around a 30 percent chance of representing a malignancy, making this an important guide for where to biopsy.
Why Are MRI Fusion Biopsies Increasingly Used?
Even a well-performed standard prostate biopsy can miss a cancer if the needle does not pass directly through the suspicious area, which is why MRI fusion biopsy has become more common. This technique fuses MRI images with real-time ultrasound to precisely target nodules identified on MRI, improving the accuracy of prostate cancer diagnosis.
What Does a Suspicious Biopsy Target Look Like?
On combined ultrasound and Doppler imaging, a nodule showing high vascularity is considered suspicious for cancer and becomes the specific target for biopsy. This targeted approach, rather than a purely random sampling technique, is now central to how prostate cancer is diagnosed and confirmed.
← PSA Velocity and the Free-to-Total PSA Ratio Explained | Series index | Staging Prostate Cancer: MRI and PSMA PET CT Scans →
This article is based on a Jivo Masterclass session conducted by Dr. Shafiq Ahmad, Senior Director, Urology, Andrology and Renal Transplant, BLK-Max Super Speciality Hospital, New Delhi, India. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
This guide is based on a live Jivo Masterclass — Dr. Shafiq Ahmad taught doctors across Africa on July 6, 2025.
FROM THE LIVE Q&A
Dr. Yagaram
What is the comparison between orchidectomy and radical prostatectomy?
Dr. Shafiq Ahmad
There is no real comparison — they serve different purposes. Orchidectomy is chosen for metastatic (stage 4) disease, such as a patient with multiple spinal metastases who cannot walk. Radical prostatectomy is chosen for patients whose expected lifespan is more than 10 years, who are fit for surgery, and who have organ-confined, locally advanced, or oligometastatic disease (one or two spots on PSMA PET). Orchidectomy is simply a form of androgen deprivation — nowadays we hardly do it routinely because injectable or oral androgen deprivation therapy is available; it's now used mainly for stage 4 disease.
Frequently Asked Questions
What are the ultrasound findings that differentiate chronic prostatitis from prostate cancer, and can tumour lysis syndrome occur at the initiation of radiotherapy?▼
On Doppler ultrasound, chronic prostatitis typically shows uniformly increased vascularity across the whole prostate, whereas prostate cancer shows increased vascularity at one specific point, such as a nodule. However, we don't rely on ultrasound alone to distinguish the two — it comes down to clinical judgement, PSA value, and age, since chronic prostatitis is a disease of younger, sexually active men in their 40s to early 50s, while prostate cancer is a disease of old age; I would be hesitant to diagnose chronic prostatitis in a 60-65 year old with a PSA of 10 and urinary symptoms — that points toward BPH with a suspicion of prostate cancer to rule out. On tumour lysis syndrome: yes, it can happen with any treatment — radiotherapy or chemotherapy — in any tumour, most often solid tumours; it is not specific to prostate cancer.
To reconfirm on orchidectomy — nowadays it's not done routinely for prostate cancer when androgen deprivation drugs are available, and it is done only where those drugs are not available — is that right?▼
Yes, that's correct. Orchidectomy is a cost-effective, one-time procedure, and increasingly patients in developing countries are also getting health insurance that covers the ongoing medications, so when it comes to overall treatment, orchidectomy can even be considered superior in efficacy compared to injectable treatment, and there's no harm in doing it. However, losing a testicle is a point of real psychological impact for a man, so if a patient can afford it or the treatment is available, I would suggest androgen deprivation therapy via injections or medication as preferable — orchidectomy remains a well-suited procedure specifically for patients with stage 4 disease.
I have a patient with bilateral paraparesis, power of the lower limbs 2/5 bilaterally, a hard prostate on digital rectal exam, and PSA greater than 100 — advanced prostate cancer with spinal metastasis causing the paraparesis was considered. In our setup we don't have hormonal therapy, so we did a bilateral orchidectomy, and the patient improved and was able to walk within five days. On follow-up he developed excessive heat, central abdominal obesity, breast enlargement, and high TSH. How should this hormonal disturbance be managed?▼
What you're describing is the androgen depletion syndrome — you have abolished testosterone, so the patient develops post-menopausal-type symptoms. In our practice, for patients who have undergone androgen deprivation, we educate them not to panic, start gabapentin and sometimes an anti-anxiety medication, and for central obesity and related issues advise calcium and vitamin D supplements, a high-protein, low-fat diet, regular exercise, and sunlight exposure, since bones become fragile and there is increased risk of coronary artery disease and hypertension. We sometimes also use denosumab if the patient is very incapacitated by hot flashes and sweating. You did the right thing for your patient — surgical castration is the most practical option where injectable androgen analogues or antagonists aren't reliably available.
In a patient with total PSA greater than 10, a digital rectal exam that does not show nodularity, and no access to biopsy, what would be your recommendation for management options?▼
False positivity of PSA is very common, so I would follow this patient regularly, first checking for infection. I would repeat the PSA after 6 weeks — if the high PSA was due to infection, a course of antibiotics should show a downward trend by then; if it doesn't trend down, you should have a high suspicion of prostate cancer. You can also check the free-to-total PSA ratio — if it's less than 25%, that supports the diagnosis. If the DRE is normal and there's no biopsy facility, you can follow the patient for a year and check PSA velocity — if it goes beyond 0.75 per year, refer to a centre with TRUS-guided biopsy or MRI facilities. With a PSA of 10-20, there is roughly a 10-30% chance of harbouring prostate cancer, so this should be investigated further rather than dismissed.
What is the management of prostatic calcification in a 60-year-old man with no obstructive symptoms, PSA within normal limits at 2.8, and a prostate that is not enlarged?▼
This is a sign of chronic prostatitis — patients with chronic infection in the prostate get calcium deposited in the glandular secretions over time, which is the mechanism behind the calcification. If the patient is asymptomatic and PSA is normal, I would not worry. If symptomatic, try medical management first, and only if that fails should you consider a surgical procedure. Prostatic calcification itself does not cause any harm — it is simply a telltale sign of chronic infection in the prostate.
How is prostate cancer confirmed after screening raises suspicion?▼
A transrectal ultrasound-guided biopsy, increasingly combined with MRI fusion technology, is the definitive way to confirm prostate cancer, though around 20 percent of men need more than one round of biopsy to reach a diagnosis.
What does a hypoechoic lesion on ultrasound mean for prostate cancer risk?▼
A hypoechoic lesion seen on transrectal ultrasound carries around a 30 percent chance of representing a malignancy, making it an important guide for where to biopsy.
Why is MRI fusion biopsy increasingly used over a standard biopsy?▼
Even a well-performed standard biopsy can miss a cancer if the needle does not pass directly through the suspicious area. MRI fusion biopsy fuses MRI images with real-time ultrasound to precisely target nodules identified on MRI.
What makes a biopsy target look suspicious on imaging?▼
On combined ultrasound and Doppler imaging, a nodule showing high vascularity is considered suspicious for cancer and becomes the specific target for biopsy, rather than relying on random sampling.
In This Series: Diagnosis and Management of Prostate Cancer
- 1.Diagnosis and Management of Prostate Cancer
- 2.Side Effects of Androgen Deprivation Therapy and How They Are Managed
- 3.Metastatic Prostate Cancer: Hormone Therapy and When Chemotherapy Is Needed
- 4.Orchidectomy Versus Radical Prostatectomy: What Is the Difference?
- 5.Prostate Biopsy and MRI Fusion Biopsy: How Prostate Cancer Is Confirmed
- 6.Why Prostate Cancer Patients Are Treated Surgically Even With Advanced Disease
- 7.Recovery After Prostate Cancer Surgery: Continence, Catheters and Follow-Up
- 8.Prostate Cancer Overview: Age, Risk and Natural History
- 9.Why Prostate Cancer Affects African and Black Men More Severely
- 10.Prostate Cancer Screening and Survival: Why Country Matters
- 11.Getting a Second Opinion for Prostate Cancer From India
- 12.Staging Prostate Cancer: MRI and PSMA PET CT Scans
- 13.Prostate Cancer Treatment by Stage: From Watchful Waiting to Surgery
- 14.PSA Testing for Prostate Cancer: What It Can and Cannot Tell You
- 15.PSA Velocity and the Free-to-Total PSA Ratio Explained
- 16.Robotic Radical Prostatectomy: How the Procedure Works
- 17.Robotic Versus Open Prostatectomy: Comparing the Outcomes